Hamilton Thorne Ltd. (HTLZF) Stock

About Hamilton Thorne Ltd.

Hamilton Thorne Ltd. specializes in the development, manufacturing, and distribution of sophisticated instruments, consumables, software solutions, and support services. These essential offerings cater to the assisted reproductive technologies (ART), broader research, and cell biology sectors. Its flagship Hamilton Thorne brand delivers advanced laser and imaging systems, alongside other bespoke equipment and supplies, primarily supporting ART and developmental biology investigations. Through its Embryotech division, the company provides laboratory testing, such as endotoxin analysis and specialized sperm assays (e.g., Sperm Motility Index, Sperm Penetration). This brand also supplies fresh and cryopreserved mouse embryos and conducts technician training and proficiency evaluations. The Gynemed brand is responsible for manufacturing and distributing various products for reproductive medicine, encompassing both clinical and laboratory equipment, disposables, and even complete ART clinic setups. Meanwhile, the Planer brand offers solutions for the secure preservation of medical and biological specimens pertinent to ART and cell biology applications. Its portfolio includes bench-top incubators, programmable freezers, logging devices, alarm systems, cryo storage units, and integrated software and sensors. Hamilton Thorne's products and services are distributed globally through a dedicated direct sales force in the United States, Germany, France, and the United Kingdom, supplemented by a robust network of international distributors. This extensive client base, spanning roughly 2,000 establishments in around 75 nations, comprises fertility clinics, hospitals, pharmaceutical and biotechnology companies, educational institutions, and other commercial and academic research entities. Its corporate headquarters are located in Beverly, Massachusetts.

Hamilton Thorne Ltd. is headquartered in US.

Hamilton Thorne Ltd. (HTLZF) stock trades at $1.59 with a market capitalization of $245.15M. The stock is valued at a price-to-earnings (P/E) ratio of -388.39, price-to-book of 3.63, price-to-sales of 3.65. Over the past 52 weeks the stock has ranged between $1.59 and $1.59, and currently trades at its 52-week high.

On profitability, Hamilton Thorne Ltd. generates a return on equity (ROE) of -1.00%, return on capital employed of 0.30%, an operating margin of 0.41%, a net profit margin of -0.90%.

Official website: www.hamiltonthorne.ltd